Nicholas Adlard

762 total citations
46 papers, 524 citations indexed

About

Nicholas Adlard is a scholar working on Pathology and Forensic Medicine, Economics and Econometrics and Rheumatology. According to data from OpenAlex, Nicholas Adlard has authored 46 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pathology and Forensic Medicine, 15 papers in Economics and Econometrics and 10 papers in Rheumatology. Recurrent topics in Nicholas Adlard's work include Multiple Sclerosis Research Studies (30 papers), Health Systems, Economic Evaluations, Quality of Life (14 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Nicholas Adlard is often cited by papers focused on Multiple Sclerosis Research Studies (30 papers), Health Systems, Economic Evaluations, Quality of Life (14 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Nicholas Adlard collaborates with scholars based in Switzerland, United Kingdom and India. Nicholas Adlard's co-authors include Imtiaz A. Samjoo, Chris Cameron, Evelyn Worthington, Luisa Klotz, Dieter A. Häring, Melody Zhao, Stuart Carroll, Felicity Allen, Rhys Pockett and Andrew Lloyd and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Archives of Disease in Childhood.

In The Last Decade

Nicholas Adlard

45 papers receiving 515 citations

Peers

Nicholas Adlard
Cynthia Madden United States
Kavitha Goyal United States
Thuan Chong Quah Singapore
Rachel Archer United Kingdom
Róisín Adams Ireland
Núria Lara Spain
Philip Laws United Kingdom
Paolo Sciattella Italy
W. Dunlop United Kingdom
F.S. Mennini Italy
Cynthia Madden United States
Nicholas Adlard
Citations per year, relative to Nicholas Adlard Nicholas Adlard (= 1×) peers Cynthia Madden

Countries citing papers authored by Nicholas Adlard

Since Specialization
Citations

This map shows the geographic impact of Nicholas Adlard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Adlard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Adlard more than expected).

Fields of papers citing papers by Nicholas Adlard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Adlard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Adlard. The network helps show where Nicholas Adlard may publish in the future.

Co-authorship network of co-authors of Nicholas Adlard

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Adlard. A scholar is included among the top collaborators of Nicholas Adlard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Adlard. Nicholas Adlard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Benedict, Ralph H. B., et al.. (2024). Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study. ClinicoEconomics and Outcomes Research. Volume 16. 55–67.
2.
3.
Baharnoori, Moogeh, Virender Bhan, Kimberly Thomas, et al.. (2022). Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada. PharmacoEconomics - Open. 6(6). 859–870. 16 indexed citations
4.
Samjoo, Imtiaz A., Luisa Klotz, Gavin Giovannoni, et al.. (2022). Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 66. 104031–104031. 10 indexed citations
5.
Thokala, Praveen, et al.. (2022). ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients. Applied Health Economics and Health Policy. 20(5). 731–742. 3 indexed citations
6.
Samjoo, Imtiaz A., Evelyn Worthington, Melody Zhao, et al.. (2021). Efficacy classification of modern therapies in multiple sclerosis. Journal of Comparative Effectiveness Research. 10(6). 495–507. 80 indexed citations
7.
Samjoo, Imtiaz A., et al.. (2021). Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. Current Medical Research and Opinion. 37(11). 1933–1944. 4 indexed citations
8.
Adlard, Nicholas, et al.. (2021). How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy. 10(2). 557–583. 7 indexed citations
9.
Samjoo, Imtiaz A., Evelyn Worthington, Chris Cameron, et al.. (2020). The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. Current Medical Research and Opinion. 36(7). 1145–1156. 5 indexed citations
10.
Nakhai-Pour, Hamid Reza, et al.. (2020). Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada. Journal of Medical Economics. 23(12). 1525–1533. 3 indexed citations
11.
Samjoo, Imtiaz A., Evelyn Worthington, Melody Zhao, et al.. (2020). Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Journal of Comparative Effectiveness Research. 9(18). 1255–1274. 45 indexed citations
12.
Samjoo, Imtiaz A., Evelyn Worthington, Chris Cameron, et al.. (2020). Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Current Medical Research and Opinion. 36(7). 1157–1166. 13 indexed citations
13.
14.
15.
Gustavsson, Anders, Deniz Simsek, Nicholas Adlard, et al.. (2016). Current Issues and Future Research Priorities for Health Economic Modelling of at Risk Population for Alzheimer’s Disease/Dementia. Value in Health. 19(7). A377–A377. 1 indexed citations
16.
Bergvall, Niklas, et al.. (2015). Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Journal of Medical Economics. 18(11). 874–885. 27 indexed citations
17.
18.
Adlard, Nicholas, Philip Kinghorn, & Emma Frew. (2014). Is the UK NICE “Reference Case” Influencing the Practice of Pediatric Quality-Adjusted Life-Year Measurement within Economic Evaluations?. Value in Health. 17(4). 454–461. 17 indexed citations
19.
20.
Morgan, Christopher Ll., et al.. (2010). Burden on UK secondary care of rotavirus disease and seasonal infections in children. Current Medical Research and Opinion. 26(10). 2449–2455. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cynthia Madden Breakdown of academic impact, for papers by Kavitha Goyal Breakdown of academic impact, for papers by Thuan Chong Quah Breakdown of academic impact, for papers by Rachel Archer Breakdown of academic impact, for papers by Róisín Adams Breakdown of academic impact, for papers by Núria Lara Breakdown of academic impact, for papers by Philip Laws Breakdown of academic impact, for papers by Paolo Sciattella Breakdown of academic impact, for papers by W. Dunlop Breakdown of academic impact, for papers by F.S. Mennini
Rankless by CCL
2026